Search

Thermo Fisher Scientific Inc

Slēgts

SektorsVeselības aprūpe

567.09 -0.97

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

565.37

Max

569.79

Galvenie mērījumi

By Trading Economics

Ienākumi

-314M

1.7B

Pārdošana

-1.2B

11B

P/E

Sektora vidējais

29.235

62.58

EPS

5.44

Dividenžu ienesīgums

0.33

Peļņas marža

15.048

Darbinieki

125,000

EBITDA

-905M

2.3B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+5.43% upside

Dividendes

By Acuity

Dividenžu ienesīgums

Sektora vidējais

0.33%

2.19%

Nākamie ieņēmumi

2026. g. 21. okt.

Nākamais dividenžu datums

2026. g. 15. okt.

Nākamais Ex dividenžu datums

2026. g. 15. sept.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

78M

196B

Iepriekšējā atvēršanas cena

568.06

Iepriekšējā slēgšanas cena

567.09

Ziņu noskaņojums

By Acuity

39%

61%

106 / 340 Rangs Healthcare

Thermo Fisher Scientific Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 24. jūl. 19:23 UTC

News
Social Media

Thermo Fisher Scientific shares are lower today despite strong Q2 results and revenue of $11.99 billion. Barclays and Deutsche Bank raised price targets to $650 and $635, respectively.

2026. g. 23. jūl. 23:01 UTC

Thermo Fisher Scientific shares declined in after-market trading, touching a session low before a slight recovery. The stock remains above its 20-day moving average.

2026. g. 22. jūl. 23:02 UTC

Social Media

Thermo Fisher Scientific is set to report earnings, with analysts estimating revenue of $11.71 billion and EPS of $5.72. Shares are higher in after-market trading.

2026. g. 21. jūl. 22:01 UTC

Thermo Fisher Scientific shares are higher in after-market hours, supported by positive market sentiment from strong earnings reports, despite recent lower finishes.

2026. g. 20. jūl. 19:46 UTC

Shares of Thermo Fisher Scientific Inc. are lower today, reflecting routine intraday fluctuations within the asset's one-month trading range.

Salīdzinājums

Cenas izmaiņa

Thermo Fisher Scientific Inc Prognoze

Cenas mērķis

By TipRanks

5.43% augšup

Prognoze 12 mēnešiem

Vidējais 599.12 USD  5.43%

Augstākais 675 USD

Zemākais 510 USD

Pamatojoties uz 19 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Thermo Fisher Scientific Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

19 ratings

14

Pirkt

5

Turēt

0

Pārdot

Noskaņojums

By Acuity

106 / 340 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product. Thermo Fisher Scientific Inc. was founded in 1956 and is headquar
help-icon Live chat